Table 2.
Glycemic control biomarkers in patients with prediabetes of the PLC and MO groups during the intervention.
| 0 wk | 6 wk | 12 wk | p # | Rate of Change 0–12 wk |
||
|---|---|---|---|---|---|---|
| Glucose (mg/dL) | PLC | 104.2 ± 15.7 | 104.5 ± 18.0 | 106.2 ± 18.0 | 0.014 | 2.1 ± 9.9 |
| MO | 103.4 ± 10.8 | 106.9 ± 8.4 | 100.6 ± 8.7 | −2.3 ± 8.6 | ||
| pΦ = 0.049; Power = 0.51 | ||||||
| HbA1c (%) | PLC | 5.83 ± 0.37 | 5.85 ± 0.42 | 5.87 ± 0.47 | 0.030 | 0.7 ± 4.2 |
| MO | 5.88 ± 0.31 | 5.90 ± 0.35 | 5.79 ± 0.37 | −1.5 ± 3.7 | ||
| pΦ = 0.026 Power = 0.61 | ||||||
| Insulin (µUI/mL) | PLC | 8.74 ± 4.25 | 8.65 ± 2.80 | 10.56 ± 5.94 | 0.007 | 27.1 ± 57.7 |
| MO | 11.11 ± 5.21 | 13.46 ± 6.01 | 12.37 ± 5.18 | 17.3 ± 31.5 | ||
| NS | ||||||
| HOMA-IR | PLC | 2.26 ± 1.25 | 2.24 ± 0.82 | 2.83 ± 1.95 | 0.003 | 32.8 ± 78.3 |
| MO | 2.86 ± 1.41 | 3.56 ± 1.58 | 3.10 ± 1.33 | 15.6 ± 34.0 | ||
| NS |
Between-group differences were assessed with a GLM with within-subject factor “visit”, the fixed factor “treatment” and the interaction “treatment × visit”. The p #-value corresponds to the “treatment × visit” factor. p Φ, ANCOVA between treatment groups with basal value as covariate. NS, not significant.